Serosurvey for SARS-CoV-2 among blood donors in Wuhan,China from September to December 2019
作者机构：National Center for Clinical LaboratoriesBeijing HospitalNational Center of GerontologyInstitute of Geriatric MedicineChinese Academy of Medical SciencesBeijing 100730China Beijing Engineering Research Center of Laboratory MedicineBeijing HospitalBeijing 100730China Department of LaboratoryWuhan Blood CenterWuhan 430030China Confirmation Laboratory for Transfusion Transmitted DiseaseInstitute of Blood Transfusion of Hubei ProvinceWuhan 430030China National Health Commission of the People's Republic of China Key Laboratory of Systems Biology of PathogensInstitute of Pathogen BiologyChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Key Laboratory of Respiratory Disease PathogenomicsChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Department of Quality ControlWuhan Blood CenterWuhan 430030China Graduate SchoolPeking Union Medical CollegeChinese Academy of Medical SciencesBeijing 100730China
出 版 物：《Protein & Cell》 (蛋白质与细胞（英文版）)
年 卷 期：2023年第14卷第1期
页 面：28-36页
核心收录：
学科分类：0710[理学-生物学] 1002[医学-临床医学] 10[医学]
主 题：severe acute respiratory syndrome coronavirus 2 coronavirus disease 2019 seroprevalence neutralizing antibodies blood donors
摘 要：The emerging of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)caused COVID-19 pandemic.The first case of COVID-19 was reported at early December in 2019 in Wuhan City,China.To examine specific antibodies against SARS-CoV-2 in biological samples before December 2019 would give clues when the epidemic of SARS-CoV-2 might start to circulate in populations.We obtained all 88,517 plasmas from 76,844 blood donors in Wuhan between 1 September and 31 December 2019.We first evaluated the pan-immunoglobin(pan-Ig)against SARS-CoV-2 in 43,850 samples from 32,484 blood donors with suitable sample quality and enough volume.Two hundred and sixty-four samples from 213 donors were pan-Ig reactive,then further tested IgG and IgM,and validated by neutralizing antibodies against SARS-CoV-2.Two hundred and thirteen samples(from 175 donors)were only pan-Ig reactive,8(from 4 donors)were pan-Ig and IgG reactive,and 43(from 34 donors)were pan-Ig and IgM reactive.Microneutralization assay showed all negative results.In addition,213 screened reactive donors were analyzed and did not show obviously temporal or regional tendency,but the distribution of age showed a difference compared with all tested donors.Then we reviewed SARS-CoV-2 antibody results from these donors who donated several times from September 2019 to June 2020,partly tested in a previous published study,no one was found a significant increase in S/CO of antibodies against SARS-CoV-2.Our findings showed no SARS-CoV-2-specific antibodies existing among blood donors in Wuhan,China before 2020,indicating no evidence of transmission of COVID-19 before December 2019 in Wuhan,China.
维普期刊数据库